Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck
Overview
The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and neck.
Full Title of Study: “Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 2013
Detailed Description
The treatment option in patients with platinum-resistant relapsed or metastatic squamous cell carcinoma of head and neck is limited. Previous randomized phase III study showed a borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the efficacy of pemetrexed in salvage setting.
Interventions
- Drug: Pemetrexed
- Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
Arms, Groups and Cohorts
- Experimental: Pemetrexed
- 500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
Clinical Trial Outcome Measures
Primary Measures
- Overall response rate
- Time Frame: 6 weeks
Secondary Measures
- Median progression-free survival
- Time Frame: 1 year
- Median overall survival
- Time Frame: 1 year
Participating in This Clinical Trial
Inclusion Criteria
- Age range: 18-65 years old – Histological confirmed incurable relapsed or metastatic squamous cell carcinoma of head and neck – Prior exposure of at least one line of platinum-containing regimen – At least one site of measurable disease according to RECIST criteria – ECOG performance status 0-1 – Life expectancy of more than 3 months – Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L – Liver function: total bilirubin, ALT and AST <1.5×UNL – Renal function: Cr<1.5×UNL, CCR≧45ml/min Exclusion Criteria:
- With curable treatment option – Prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used with radiotherapy – History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix – Significant active infection – Pregnant or lactating women
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Fudan University
- Provider of Information About this Clinical Study
- Principal Investigator: Ye Guo, Dr. – Fudan University
- Overall Official(s)
- Ye Guo, MD, Principal Investigator, Fudan University
- Overall Contact(s)
- Ye Guo, MD, 86 21 64175590, pattrick_guo@msn.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.